New Drugs and Therapies for Spinal Cord Injuries

Neuraxo Biopharmaceuticals, a German biopharmaceutical company stands for pioneering the therapy of acute and chronic Spinal Cord Injuries with its proprietary technology platform: the Regeneration Promoting Treatment (RPT).

As a first clinical application of the RPT Neuraxo is focusing on the clinical development of Cordaneurin^® - a drug for the treatment of acute Spinal Cord Injuries which received Orphan Drug Status in 2004. In pre-clinical studies Cordaneurin^® has already demonstrated its high efficacy in extensive recovery of sensory and motor function.

As a second application Neuraxo will take up the challenge to develop a therapy also for chronic injured patients. This cure called CordaChron^TM will include additional components to Cordaneurin^® such as the patent protected nerve growth stimulating factor, the chemokine SDF-1gamma.

Neuraxo's pipeline is filled with additional new and promising drug candidates in the field of neurotherapeutic drugs.

NEURAXO - New Dynamics for Neural Regeneration